The DNAJC13 Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of MES-OV cells with disrupted DNAJC13 expression. Generated by CRISPR/Cas9-mediated gene disruption, this polyclonal knockout cell model enables loss-of-function studies without clonal selection artifacts. It provides a genetically defined platform for investigating DNAJC13-dependent endosomal trafficking and retromer biology.
These knockout cells are derived from the MES-OV human ovarian clear cell carcinoma cell line, an established epithelial ovarian cancer model. MES-OV cells retain characteristic features of ovarian clear cell carcinoma, including relevant oncogenic signaling networks and epithelial morphology. This cancer cell background offers a unique platform for studying how endosomal sorting and protein trafficking pathways intersect with tumor cell biology, drug response, and cellular stress mechanisms. The MES-OV host cells are widely employed in cancer research, providing a robust context for genetic perturbation studies aimed at dissecting membrane trafficking in malignancy.
DNAJC13, also known as RME-8, functions as a co-chaperone orchestrating endosomal protein sorting and retromer-mediated retrograde transport from endosomes to the trans-Golgi network. It acts downstream of PI(3)P and Hsc70, regulated by Rab GTPases, and interacts directly with the retromer complex (VPS35, VPS26, VPS29), the WASH complex, and SNX1/2. These interactions facilitate actin nucleation and cargo trafficking, governing recycling and degradation of transmembrane receptors. DNAJC13 controls retrograde transport of Sortilin, CI-MPR, and Wntless, and influences EGFR degradation, intersecting with growth factor signaling and autophagy.
In the MES-OV ovarian cancer context, DNAJC13 knockout disrupts the endosomal-lysosomal system, allowing exploration of how endosome dynamics influence tumor cell homeostasis. Although primarily associated with Parkinson disease and neurodegeneration, DNAJC13??s role in protein trafficking may affect cancer-relevant processes like receptor turnover, autophagy, and therapy response. This model enables interrogation of retromer-dependent transport contributions to ovarian cancer cell proliferation and survival, while also serving as an isogenic platform for studying neurodegeneration pathways in a non-neuronal background.
The DNAJC13 Knockout MES-OV Polyclonal Cells are suited for endosomal trafficking studies, retromer functional analysis, and autophagy research. Users can assess cargo receptor fate via EGFR degradation and transferrin recycling assays, examine retromer complex integrity by co-immunoprecipitation, and evaluate autophagy flux. Additional applications include immunofluorescence, flow cytometry for protein quantification, and high-content screening for trafficking modulators. This knockout model supports drug discovery targeting the endosomal pathway and provides a resource for Parkinson??s disease modeling. For additional information, please contact Ascent Research.
